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Abstract
Background: Visceral fat accumulation in overweight status has been resulted in changes of fatty acid profiles. The
fatty acids profiles can be altered by fatty acid desaturase; the activity of which is highly associated with obesity and
other metabolic diseases. We hypothesized that fatty acid composition, desaturase activity, and accumulation of
visceral fat are interrelated. Thus, the aim of this study was to investigate the association between increased visceral fat
area and alterations in plasma fatty acid profile in overweight subjects with different amounts of visceral fat.
Methods: Healthy overweight subjects (25.0 kg/m2 ≤ BMI < 30 kg/m2, n=232) were classified into lower (T1), middle
(T2), and upper tertiles (T3) according to L4 visceral fat area (T1: <71.8 cm2, T2: 71.8 cm2–99.6 cm2, T3: >99.6 cm2).
Results: The T3 group showed higher amounts of cis-10-heptadecenoic acid and activity of C16 Δ9-desaturase and
C18 Δ9-desaturase and lower activity of Δ5-desaturase than the T1 group. Additionally, the T3 group showed higher
amounts of saturated fatty acids, myristic acid, palmitic acid, stearic acid, monounsaturated fatty acids, palmitoleic acid,
oleic acid, n-6 polyunsaturated fatty acids, linoleic acid, dihomo-γ-linolenic acid, arachidonic acid, n-3 PUFAs, and
docosapentaenoic acid than the T1 and T2 groups.
Conclusions: This study indicates that greater than a certain area (>99.6 cm2) of visceral fat is needed to observe
altered levels of individual fatty acid species and desaturase activities. The results suggest that increased activity of C16
Δ9-desaturase and C18 Δ9-desaturase in parallel with decreased Δ5-desaturase activity may be a causative factor in
disturbed fatty acid metabolism.
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Background
Obesity, particularly abdominal obesity, results from an
increase in visceral fat. Visceral fat accumulation in over-
weight status has been suggested to lead to changes in the
composition of lipids, lipoproteins [1], and fatty acids [2].
The fatty acid profile can be altered by diet as well as fatty
acid desaturases [3]. These enzymes play an important
role in regulating whole-body lipid composition [4, 5], and
their activity is highly associated with obesity and other
metabolic diseases [6]. For example, high Δ9-desaturase
(D9D) activity has been associated with obesity, hypertri-
glyceridemia, metabolic syndrome, and increased risk of
insulin resistance (IR) [6]; while, Δ5-desaturase (D5D) ac-
tivity is negatively associated with the risk of metabolic
syndrome and cardiovascular death [7–9]. Additionally,
hepatic lipid composition changes caused by obesity are
related to desaturase expression [10]. The results of a re-
cent meta-analysis confirmed that the long-chain polyun-
saturated fatty acid (PUFA) profile is altered in obesity;
the differences observed in desaturase activity may be re-
sponsible for the disturbance of long-chain PUFA metab-
olism in overweight/obesity [11]. The study indicated high
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Δ6-desaturase (D6D) activity and low D5D activity in
overweight and/or obese subjects. In detail, they observed
low linoleic acid (C18:2, n-6) levels and high dihomo-γ-
linolenic acid (C20:3, n-6) levels. Amount of dihomo-γ-
linolenic acid (C20:3, n-6) in common foods is very low,
therefore, the results mean that activity of D6D that con-
tributes to convert linoleic acid (C18:2, n-6) to dihomo-γ-
linolenic acid (C20:3, n-6) was increased in overweight
and/or obese subjects. In addition, in those subjects, al-
though their dihomo-γ-linolenic acid (C20:3, n-6) was
high, the ratio of arachidonic acid (C20:4, n-6) to
dihomo-γ-linolenic acid (C20:3, n-6) was low; that
means the activity of D5D that converts dihomo-γ-
linolenic acid (C20:3, n-6) to arachidonic acid (C20:4,
n-6) was decreased [11]. Therefore, overweight and/or
obese status, fatty acid composition, and desaturase
activity are related to each other.
In this study, we hypothesized that fat distribution af-
fects fatty acid composition and desaturase activity even
in overweight individuals have similar fat mass; because
fatty acid composition, desaturase activity, and accumu-
lation of visceral fat are interrelated to some extent [12–
15]. Moreover, the amount of visceral fat is important
for assessing the impact on metabolic disease [16].
Therefore, we focused on the association between in-
creased visceral fat area and alterations in the plasma
fatty acid profile in overweight subjects.
Methods
Study subjects and design
Participants were recruited through advertisements in
Seoul. Based on data from the Clinical Nutrition Labora-
tory, Yonsei University, overweight subjects [25.0 kg/m2 ≤
body mass index (BMI) <30 kg/m2] were referred to the
department of Endocrinology, Yonsei University Hospital.
They were interviewed and underwent blood and health
tests; those who met the study criteria were then recom-
mended to participate in this study. The participation cri-
teria were age between 20 and 65 years; absence of
pregnancy or breast-feeding; stable body weight (body-
weight change < 1 kg over the 3 months before screening);
no hypertension, type 2 diabetes, cardiovascular disease,
or thyroid disease; and no use of any medication affecting
body weight, lipid/fatty acid profiles, energy expenditure,
or glucose control for the past 6 months. Additionally,
only those who voluntarily consented to the program
were included. Subjects were excluded if they drank
more than 70 g of alcohol per week or had a prior
history of Cushing disease, malignancy, or other liver
diseases, including chronic viral hepatitis, auto-
immune hepatitis, primary biliary cirrhosis, and drug-
induced liver disease. Finally, subjects with a history
of intentional weight loss in the last 6 months were
excluded. In total, 232 healthy overweight (BMI
between 25.0 and 30.0 kg/m2) individuals were en-
rolled and classified into lower (T1), middle (T2), and
upper tertiles (T3) according to visceral fat area at L4
(T1: <71.8 cm2, T2: 71.8 cm2–99.6 cm2, T3:
>99.6 cm2). Associations between visceral fat content
and fatty acid profiles were observed cross-sectionally.
We gave all subjects a careful explanation of the pur-
pose of the study and received written consent prior
to their participation. The protocol used in the study
was approved by the Institutional Review Board of
Yonsei University and Yonsei University Severance
Hospital according to the Helsinki Declaration.
Blood collection
Venous blood specimens were collected after an over-
night fast of at least 12 h. The blood samples were col-
lected in serum tubes and EDTA-treated whole-blood
tubes (BD Vacutainer; Becton, Dickinson and Company,
Franklin Lakes, NJ, USA). The samples were centrifuged
to obtain plasma and serum from the whole blood and
then stored at −80 °C.
Anthropometric parameters and body composition
measurements
Body weight (Inbody370; Biospace, Cheonan, Korea) and
height (GL-150; G-tech International, Uijeongbu, Korea)
were measured, and BMI (kg/m2) was calculated from
these data. Waist circumference was assessed directly on
the skin with a plastic measuring tape at the umbilical
level. Systolic and diastolic blood pressure (BP) were
measured with the participant in the supine position
after a 20-min resting period. BP was assessed twice with
an automatic BP monitor (FT-200S; Jawon Medical,
Gyeongsan, Korea), and the average value of the two
measurements was used.
Abdominal fat distribution data at L1 and L4 were
obtained via computed tomography (CT) scanning
using a GE Medical System HiSpeed Advantage® sys-
tem (Milwaukee, WI, USA). The scanning parameters
were a slice thickness of 1 mm at 200 mA and 120
kVp, with a 48-cm field of view. The body compos-
ition of the study subjects was measured with dual-
energy X-ray absorptiometry (DEXA; Discovery A;
Hologic, Bedford, MA, USA) to determine fat mass,
lean body mass and fat percentage. The results were
analyzed by volume integration software (APEX 4.0.2
[13.4.1]; Hologic, Bedford, MA, USA).
Serum fasting glucose, serum insulin, and homeostatic
model assessment (HOMA) of IR
Fasting glucose was assessed via the hexokinase method
using Glucose Kits (Roche, Mannheim, Germany). Serum
insulin was measured by an immunoradiometric assay
using an Insulin Immunoradiometric Assay Kit
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(DIAsource, Louvain, Belgium). The resulting color reac-
tion was monitored via a Hitachi 7600 system (Hitachi,
Tokyo, Japan) for serum fasting glucose and an SR-300
system (Stratec, Birkenfeld, Germany) for insulin. IR was
calculated from the HOMA using the following equation:
HOMA-IR = [fasting insulin (μIU/mL) × fasting glucose
(mg/dL)]/405.
Serum fasting lipid profile and apolipoproteins
Fasting total cholesterol (TC) and triglyceride (TG)
were measured through enzymatic assays using CHOL
and TG Kits (Roche, Mannheim, Germany), respect-
ively. Analysis of high-density lipoprotein (HDL-)
cholesterol was conducted via selective inhibition
using an HDL-C Plus Kit (Roche, Mannheim,
Germany). The result of the color reaction was mea-
sured with a Hitachi 7600 autoanalyzer (Hitachi,
Tokyo, Japan). Low-density lipoprotein (LDL-) choles-
terol levels were calculated by the Friedewald formula:
LDL-cholesterol = TC – [HDL-cholesterol + (TG/5)].
Serum fasting apolipoprotein B and apolipoprotein A-I
were measured via immunoturbidimetric assays with
Apolipoprotein B and Apolipoprotein A-I Kits (Roche,
Mannheim, Germany), respectively. Turbidity was
assessed using a Cobas Integra 800 autoanalyzer (Roche,
Rotkreuz, Switzerland).
Serum high-sensitivity C-reactive protein (hs-CRP)
The serum hs-CRP concentration was analyzed with CRP
kits (Roche, Mannheim, Germany), and turbidity was
monitored using a Hitachi 7600 autoanalyzer (Hitachi,
Tokyo, Japan).
Gas chromatography-mass spectrometry (GC-MS) analysis
The details regarding GC-MS analysis have been previ-
ously described [17]. Briefly, GC-MS analysis of metabo-
lites in plasma was carried out using an Agilent
Technologies 7890 N gas chromatograph coupled to an
Agilent Technologies 5977A quadrupole mass selective
spectrometer with a triple-axis detector (Agilent, Palo
Alto, CA) operated in electron ionization mode at 70 eV
with a mass scan range of m/z 50–800. Derivatized sam-
ples were separated on a VF-WAX column (Agilent
Technologies, Middelburg, The Netherlands) with an
oven temperature ramp from 50 °C to 230 °C. The
carrier gas was helium set at constant flow mode
(1.0 mL/min). The identification of each metabolite in
the samples was confirmed by comparing their relative
retention times and mass spectra with those of authentic
standard compounds. The relative levels of metabolites
were calculated by comparing their peak areas to that of
the internal standard compound.
Fatty acid desaturase activities and elongase activities
were obtained indirectly by calculating fatty acid ratios
of products to precursors. The equations are as fol-
lows: C16 Δ9-desaturase = Palmitoleic acid/Palmitic
acid; C18 Δ9-desaturase = Oleic acid/Stearic acid; Δ6-
desaturase = γ-Linolenic acid/Linoleic acid; Elongase
activity = Stearic acid/Palmitic acid.
Statistical analysis
Statistical analysis was carried out in SPSS version 23.0
(IBM/SPSS, Chicago, IL, USA). The skewed variables
were tested by logarithmic transformation. One-way
analysis of variance (ANOVA) with a Bonferroni post
hoc test was performed for continuous variables, and a
chi-square test was applied to analyze nominal variables.
A general linear model was used to adjust for the poten-
tial confounding factors, including age, sex, smoking,
drinking, and BMI. Pearson’s correlation coefficient was
analyzed to find relationships between variables and par-
tial correlation analysis was performed to adjust for the
confounding factors. A heat map was created via Mul-
tiple Experiment Viewer (MeV) version 4.9.0 (http://
www.tm4.org/) to visualize the relationships between
variables. The outcomes are stated as the mean ± stand-
ard error (SE). The results were considered statistically
significant at p < 0.05.
Results
General characteristics of the study subjects
The general characteristics of 232 overweight subjects
distributed over the tertiles of L4 visceral fat area are
presented in Table 1. Of the three groups that we de-
fined according to L4 visceral fat area (T1: <71.8 cm2,
T2: 71.8 cm2–99.6 cm2, T3: >99.6 cm2), the T3 group
was on average older and heavier than the others. After
adjusting for age, sex, smoking, drinking, and BMI, the
T2 and T3 groups showed higher fasting insulin, and a
higher HOMA-IR index than the T1 group. After
adjusting for confounding factors, the T3 group
showed higher waist circumference, diastolic BP, and
hs-CRP and lower HDL-cholesterol than did the T1
group as well as higher TG, TC, LDL-cholesterol, and
apolipoprotein B than did the T1 and T2 groups.
When each tertile was compared to the total subjects,
there were no significant differences between the total
subjects and the T2 group. The subjects in the T1
group were younger; had lower waist circumference,
waist-to-hip ratio, diastolic BP, glucose, TG, total-
cholesterol, LDL-cholesterol, apolipoprotein B, and
hs-CRP; and had higher HDL-cholesterol than the
total subjects. The subjects in the T3 group were
older; showed increased waist circumference, waist-to-
hip ratio, diastolic BP, TG, TC, LDL-cholesterol, apoli-
poprotein B, and hs-CRP; and showed decreased
HDL-cholesterol compared to the total subjects.
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Visceral fat area and body composition measured by CT
and DEXA
Table 2 shows visceral fat area measured using CT at
L1 and L4 and body composition measured using
DEXA. After adjusting for age, sex, smoking, drink-
ing, and BMI, the T3 group showed the greatest vis-
ceral fat area at the L1 and L4 levels, whereas the
T1 group showed a greater subcutaneous fat area at
the L4 level than did the T3 group. At the L1 level,
the T3 and T2 groups showed higher visceral/sub-
cutaneous fat ratios (VSRs) than the T1 group, and
at the L4 level, the T3 group showed the highest
VSR. With respect to body composition measured
using DEXA, the T1 and T3 groups showed higher
total fat percentages than the T2 group, and the T3
group had a greater total fat mass than the T2 group
(Table 2).
Plasma fatty acid profile according to L4 visceral fat area
Table 3 shows the plasma fatty acid profiles of the sub-
jects according to L4 visceral fat area. After adjusting for
age, sex, smoking, drinking, and BMI, the T3 group
showed higher amounts of saturated fatty acids (SFAs),
myristic acid (C14:0), palmitic acid (C16:0), stearic acid
(C18:0), monounsaturated fatty acids (MUFAs), palmito-
leic acid (C16:1, n-7), and oleic acid (C18:1, n-9) than
the T1 and T2 groups. The T3 group also showed higher
cis-10-heptadecenoic acid (C17:1, n-7) than the T1
group. Similarly, after adjusting for age, sex, smoking,
drinking, and BMI, the T3 group showed higher n-6
PUFAs, linoleic acid (C18:2, n-6), dihomo-γ-linolenic
acid (C20:3, n-6), and arachidonic acid (C20:4, n-6)
than the T1 and T2 groups. Additionally, after adjust-
ing for age, sex, smoking, drinking, and BMI, the T3
group showed the highest n-3 PUFA level and had
higher docosapentaenoic acid (C22:5, n-3) than the
T1 and T2 groups. Furthermore, the T3 group
showed higher estimated activity levels of C16 Δ9-
desaturase and C18 Δ9-desaturase and a lower activ-
ity of Δ5-desaturase than the T1 group (Table 3).
Correlation analysis of CT and DEXA parameters, major
fatty acids, and fatty acid desaturases in all study
participants
Based on the results of GC-MS analysis, fatty acids
and fatty acid desaturases that showed significance
after adjusting for confounding factors, including age,
sex, smoking, drinking, and BMI, were included in a
correlation analysis with CT and DEXA parameters.
As shown in Fig. 1, before adjusting for confounding
factors, VFA at L4 showed significant positive correla-
tions with C16 Δ9-desaturase (r = 0.237, p < 0.001)
and C18 Δ9-desaturase (r = 0.148, p = 0.024); and a
significant negative correlation with Δ5-desaturase (r
= −0.288, p < 0.001). In addition, VFA at L4 showed
strong positive associations with all major fatty acids
except for arachidonic acid (C20:4, n-6). These signifi-
cant correlations remained after adjusting for the con-
founding factors. VFA at L1, before adjusting for
confounding factors, showed a significant negative
correlation with Δ5-desaturase (r = −0.217, p = 0.001)
and significant positive correlations with all major
Table 2 Abdominal fat area and body composition
Lower tertile (T1, n = 77) Middle tertile (T2, n = 78) Upper tertile (T3, n = 77) pa pb pc
VFA at L4 < 71.8 cm2 71.8 cm2 ≤ VFA at L4 ≤ 99.6 cm2 VFA at L4 > 99.6 cm2
CT evaluation (L1)
Total fat area (cm2) 224.7 ± 5.16b 244.4 ± 5.37a 269.9 ± 6.13a <0.001 <0.001 <0.001
Visceral fat area (cm2) 81.7 ± 2.64c 111.9 ± 3.58b 133.0 ± 4.83a <0.001 <0.001 <0.001
Subcutaneous fat area (cm2) 143.0 ± 3.83 132.6 ± 4.04 136.9 ± 4.41 0.197 0.338 0.869
Visceral/subcutaneous fat ratio 0.60 ± 0.02b 0.93 ± 0.05a 1.07 ± 0.06a <0.001 <0.001 <0.001
CT evaluation (L4)
Total fat area (cm2) 289.6 ± 5.04b 294.4 ± 5.17b 325.5 ± 4.35a <0.001 <0.001 <0.001
Visceral fat area (cm2) 56.7 ± 1.17c 86.6 ± 0.92b 121.3 ± 1.93a <0.001 <0.001 <0.001
Subcutaneous fat area (cm2) 232.9 ± 4.79a 207.8 ± 5.06a,b 204.2 ± 4.79b <0.001 0.140 0.005
Visceral/subcutaneous fat ratio 0.25 ± 0.01c 0.44 ± 0.01b 0.63 ± 0.02a <0.001 <0.001 <0.001
DEXA evaluation
Fat percentage (%) 30.8 ± 0.63a 30.0 ± 0.67b 30.6 ± 0.67a 0.667 0.001 0.009
Fat mass (g) 22,156.2 ± 404.0a,b 21,711.5 ± 439.9b 22,487.8 ± 447.7a 0.442 0.001 0.023
Lean body mass (g) 48,345.1 ± 1031.4 49,338.9 ± 1071.0 49,637.8 ± 1025.6 0.658 0.402 0.158
Mean ± SE. pa-values derived from a One-way ANOVA. pb-values were adjusted for age, sex, smoking, and drinking. pc-values were adjusted for age, sex,
smoking, drinking, and BMI. All p < 0.05 marked with letters were derived from Bonferroni post hoc test at pc-values; no significant differences are marked with the
same letter and significant differences are marked with different letters
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fatty acids; but no significant correlation with C16
Δ9-desaturase or C18 Δ9-desaturase was found. After
adjustment, myristic acid (C14:0), oleic acid (C18:1,
n-9), dihomo-γ-linolenic acid (C20:3, n-6), docosapen-
taenoic acid (C22:5, n-3), saturated fatty acids, and
monounsaturated fatty acids showed significant posi-
tive correlations with VFA at L1; and the significant
correlations with regard to the fatty acid desaturases
remained the same as prior to the adjustment.
Discussion
In contrast to subcutaneous fat, visceral adipose tissues
are metabolically active, sensitive to lipolysis, and
insulin-resistant [15]. Because of these characteristics,
Table 3 GC-MS analysis of fatty acids in the subjects according to tertiles of visceral fat area (VFA) at L4
Relative peak area Lower tertile (T1, n = 77) Middle tertile (T2, n = 78) Upper tertile (T3, n = 77) pa pb pc
VFA at L4 < 71.8 cm2 71.8 cm2 ≤ VFA at L4 ≤ 99.6 cm2 VFA at L4 > 99.6 cm2
Saturated fatty acids 6.200 ± 0.111b 6.350 ± 0.169b 7.086 ± 0.139a <0.001 0.002 0.002
Lauric acid (C12:0) 0.023 ± 0.001 0.028 ± 0.002 0.031 ± 0.002 0.002 0.072 0.059
Myristic acid (C14:0) 0.200 ± 0.009b 0.230 ± 0.014b 0.289 ± 0.015a <0.001 0.001 0.001
Pentadecylic acid (C15:0) 0.037 ± 0.001 0.041 ± 0.002 0.044 ± 0.001 0.003 0.147 0.149
Palmitic acid (C16:0) 4.074 ± 0.081b 4.128 ± 0.104b 4.613 ± 0.096a <0.001 0.002 0.002
Stearic acid (C18:0) 1.739 ± 0.028b 1.799 ± 0.052b 1.969 ± 0.037a <0.001 0.018 0.022
Arachidic acid (C20:0) 0.038 ± 0.001 0.038 ± 0.001 0.041 ± 0.001 0.060 0.194 0.262
Behenic acid (C22:0) 0.090 ± 0.003 0.087 ± 0.003 0.098 ± 0.003 0.017 0.049 0.091
Monounsaturated fatty acid 1.198 ± 0.029b 1.267 ± 0.047b 1.429 ± 0.036a <0.001 0.003 0.003
Palmitoleic acid (C16:1, n-7) 0.139 ± 0.007b 0.149 ± 0.007b 0.183 ± 0.008a <0.001 0.002 0.003
Cis-10-heptadecenoic acid (C17:1, n-7) 0.011 ± 0.000b 0.012 ± 0.001a,b 0.014 ± 0.000a <0.001 0.022 0.025
Oleic acid (C18:1, n-9) 0.984 ± 0.022b 1.043 ± 0.038b 1.162 ± 0.029a <0.001 0.004 0.004
Eicosenoic acid (C20:1, n-9) 0.009 ± 0.000 0.011 ± 0.001 0.011 ± 0.000 0.180 0.556 0.586
Erucic acid (C22:1, n-9) 0.009 ± 0.001 0.009 ± 0.001 0.009 ± 0.001 0.832 0.840 0.824
Nervonic acid (C24:1, n-9) 0.046 ± 0.001 0.044 ± 0.001 0.049 ± 0.002 0.099 0.197 0.297
Polyunsaturated fatty acids (n-6) 2.685 ± 0.052b 2.691 ± 0.059b 2.973 ± 0.049a <0.001 0.004 0.003
Linoleic acid (C18:2, n-6) 1.980 ± 0.039b 2.001 ± 0.048b 2.205 ± 0.038a <0.001 0.005 0.004
γ-linolenic acid (C18:3, n-6) 0.029 ± 0.002 0.030 ± 0.002 0.035 ± 0.002 0.104 0.438 0.343
Eicosadienoic acid (C20:2, n-6) 0.018 ± 0.001 0.021 ± 0.001 0.022 ± 0.001 0.017 0.251 0.212
Dihomo-γ-linolenic acid (C20:3, n-6) 0.095 ± 0.003b 0.101 ± 0.004b 0.118 ± 0.004a <0.001 0.007 0.012
Arachidonic acid (C20:4, n-6) 0.532 ± 0.013b 0.510 ± 0.012b 0.558 ± 0.013a 0.030 0.040 0.038
Docosatetraenoic acid (C22:4, n-6) 0.030 ± 0.001 0.029 ± 0.001 0.034 ± 0.001 0.006 0.028 0.061
Polyunsaturated fatty acids (n-3) 0.357 ± 0.016b 0.415 ± 0.020b 0.499 ± 0.021a <0.001 0.039 0.047
α-linolenic acid (C18:3, n-3) 0.079 ± 0.004 0.100 ± 0.009 0.113 ± 0.006 0.002 0.293 0.270
Eicosapentaenoic acid (C20:5, n-3) 0.080 ± 0.005 0.092 ± 0.006 0.113 ± 0.006 <0.001 0.393 0.494
Docosapentaenoic acid (C22:5, n-3) 0.036 ± 0.001b 0.040 ± 0.002b 0.049 ± 0.002a <0.001 0.013 0.011
Docosahexaenoic acid (C22:6, n-3) 0.162 ± 0.009 0.183 ± 0.011 0.225 ± 0.014 0.001 0.094 0.113
Ratio n-6/n-3 8.434 ± 0.321 7.350 ± 0.284 6.587 ± 0.244 <0.001 0.149 0.191
C16 Δ9-desaturasea 0.033 ± 0.001b 0.035 ± 0.001a,b 0.039 ± 0.001a 0.002 0.021 0.029
C18 Δ9-desaturaseb 0.565 ± 0.008b 0.577 ± 0.008a,b 0.589 ± 0.008a 0.102 0.047 0.036
Δ6-desaturasec 0.015 ± 0.001 0.015 ± 0.001 0.016 ± 0.001 0.579 0.815 0.813
Δ5-desaturased 6.008 ± 0.217a 5.368 ± 0.163a,b 4.945 ± 0.143b <0.001 0.025 0.036
Elongasee 0.432 ± 0.006 0.437 ± 0.006 0.430 ± 0.006 0.652 0.446 0.463
Mean ± SE. pa-values derived from a One-way ANOVA. pb-values were adjusted for age, sex, smoking, and drinking. pc-values were adjusted for age, sex, smoking,
drinking, and BMI. All p < 0.05 marked with letters were derived from Bonferroni post hoc test at pc-values; no significant differences are marked with the same let-
ter, and significant differences are marked with different letters. aC16 Δ9-desaturase = Palmitoleic acid/Palmitic acid. bC18 Δ9-desaturase = Oleic acid/Stearic acid.
cΔ6-desaturase = γ-Linolenic acid/Linoleic acid. dΔ5-desaturase = Arachidonic acid/dihomo-γ-linolenic acid. eElongase activity = Stearic acid/Palmitic acid
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visceral obesity causes several metabolic dysregula-
tions including altered lipid profiles (e.g. high levels
of TG and apolipoprotein B and low levels of HDL-
cholesterol), altered glucose homeostasis (e.g. high
levels of glucose and insulin and high HOMA-IR in-
dices), and deteriorative inflammation status (e.g. high
hs-CRP) [18, 19].
Due to the hyperlipolytic properties of the visceral adi-
posity, excess visceral fat releases large amount of fatty
acids; hence, influx of fatty acids from visceral adipose
tissues to the liver via the portal vein is increased [20–
23]. In addition, Nielsen et al. [23] demonstrated that
fatty acid delivery from visceral fat into hepatocytes in-
creases with increasing visceral fat mass. This leads to
increased fatty acid availability in hepatocytes, thereby
stimulating hepatic synthesis and secretion of TG via its
incorporation into TG-rich lipoproteins such as very
low-density lipoproteins (VLDLs) [21, 23, 24]; finally,
circulating TG increase according to visceral fat accu-
mulation. Moreover, both the concentrations of portal
vein fatty acids and the levels of systemic circulating
fatty acids showed significant and positive relationships
with visceral adipose tissues [23]. Indeed, in the present
study, the T3 group showed increased total circulating
fatty acids (SFAs, MUFAs, and PUFAs), TG, and apoli-
poprotein B, a major component of VLDL, compared to
the T1 and T2 groups; again, these results mean that TG
was synthesized in the liver from the fatty acids released
from the large amount of visceral adipose tissue in the
T3 group.
With regards to circulating fatty acid composition, the
present study indicates that overweight subjects in the
T3 group (visceral fat area at L4 >99.6 cm2) showed al-
tered levels of individual fatty acids, including myristic
acid (C14:0), palmitic acid (C16:0), stearic acid (C18:0),
palmitoleic acid (C16:1, n-7), oleic acid (C18:1, n-9), cis-
10-heptadecenoic acid (C17:1, n-7), linoleic acid (C18:2,
n-6), dihomo-γ-linolenic acid (C20:3, n-6), arachidonic
acid (C20:4, n-6), and docosapentaenoic acid (C22:5, n-
3), and altered estimated activities of C16 Δ9-desaturase,
C18 Δ9-desaturase, and Δ5-desaturase after adjusting
for age, sex, smoking, drinking, and BMI. However, there
were no significant differences in individual fatty acid
levels or desaturase activity between the T1 and T2
groups, although the T2 group had higher serum insulin
and HOMA-IR index than the T1 group. These results
Fig. 1 Correlation matrix of CT and DEXA parameters, major fatty acids, and fatty acids desaturases in all study participants before and after
adjusting for confounding factors. Correlations were obtained by deriving Pearson’s correlation coefficient (left box). Age, sex, smoking, drinking,
and BMI were adjusted (partial correlation, right box). Red indicates a positive correlation and Blue indicates a negative correlation
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suggest that greater than a certain area (>99.6 cm2)
of visceral fat is needed to observe altered levels of
individual fatty acid species and desaturase activity.
Indeed, according to our correlation analysis, a larger
accumulation of visceral fat area at L4 was associ-
ated with higher activities of C16 Δ9-desaturase and
C18 Δ9-desaturase and lower activity of Δ5-
desaturase; since fatty acid desaturases affect fatty
acid profile [3], the differences in fatty acid profiles
across the tertile groups can be elucidated by the
correlations between visceral fat area and fatty acid
desaturases.
In this study, the amount of total SFAs in plasma was
significantly higher in the T3 group than those in the T1
and T2 groups; these SFAs include palmitic acid (C16:0)
and stearic acid (C18:0), which are related to the inci-
dence of type 2 diabetes [25, 26]. Additionally, total
SFAs may increase cardiovascular disease risk by in-
creasing levels of LDL-cholesterol and TC [27]. In-
deed, the T3 group of this study showed higher TC
and LDL-cholesterol than the T1 and T2 groups.
Similarly, the level of total MUFAs, particularly
plasma oleic acid (C18:1, n-9) and palmitoleic acid
(C16:1, n-7), increased in the T3 group. We also
found that overweight individuals in the T3 group
had increased stearic acid (C18:0), oleic acid (C18:1,
n-9), and C18 Δ9-desaturase. This might be explained
by oversupply of fatty acids from excess visceral fat
and altered activity of fatty acid desaturase according
to visceral fat area.
Overweight individuals in the T3 group also had in-
creased palmitic acid (C16:0), palmitoleic acid (C16:1, n-
7), and C16 Δ9-desaturase. The serum concentration of
palmitoleic acid (C16:1, n-7) mostly reflects de novo
hepatic fatty acid synthesis from palmitic acid (16:0) by
C16 Δ9-desaturase [28–30]; thus, high levels of palmito-
leic acid (C16:1, n-7) in the T3 group indicate enhanced
activity of C16 Δ9-desaturase with increasing visceral fat
area. High levels of this particular fatty acid have been
associated with an increased risk of cardiovascular
disease as it has been positively associated with meta-
bolic syndrome [7], including hypertriglyceridemia
[31] and abdominal obesity [32]. Indeed, the T3 group
in this study showed higher serum TG, waist circum-
ference, and waist-to-hip ratio than the T1 group.
Additionally, mice supplemented with palmitoleic acid
(C16:1, n-7) presented higher fat deposition, hepatic
steatosis, and increased hepatic expression of sterol
regulatory element-binding protein 1c and fatty acid
synthase, demonstrating the pro-lipogenic effect of
this MUFA [33]. Therefore, high levels of palmitoleic
acid (C16:1, n-7) via enhanced C16 Δ9-desaturase ac-
tivity in overweight subjects with high visceral fat
area may exacerbate fat accumulation.
The levels of total n-6 PUFAs, particularly linoleic acid
(C18:2 n-6), dihomo-γ-linolenic acid (C20:3, n-6), and
arachidonic acid (C20:4, n-6), were higher in the T3
group than those in the T1 and T2 groups. The n-6
PUFAs are thought to promote adipogenesis and in-
crease the expression of lipogenic genes [34, 35]. The
dihomo-γ-linolenic acid (C20:3, n-6) content of common
foods is very low. Additionally, there was no significant
difference in the level of Δ6-desaturase across the tertile
groups. Thus, the increased dihomo-γ-linolenic acid
(C20:3, n-6) content cannot be explained by a high diet-
ary intake of dihomo-γ-linolenic acid (C20:3, n-6) or Δ6-
desaturase but rather could indicate reduced Δ5-
desaturase activity in overweight subjects with a high
visceral fat area. Therefore, the limited rate of conver-
sion of dihomo-γ-linolenic acid (C20:3, n-6) to arachi-
donic acid (C20:4, n-6) may also contribute to the
accumulation of dihomo-γ-linolenic acid (C20:3, n-6)
among the plasma lipids, which predicts an increased risk
of metabolic syndrome and type 2 diabetes [2, 36, 37]. In
contrast to n-6 PUFAs, this study showed only slight dif-
ferences in the levels of n-3 PUFAs, specifically docosa-
pentaenoic acid (C22:5, n-3), which was higher in the T3
group than that in the T1 and T2 groups.
In addition to altered fatty acid desaturase activity, the
altered fatty acid levels and metabolic dysregulations ob-
served in this study can also be explained by dysfunction
of visceral adipose tissues. Adipose tissue dysfunction,
which is involved in atherosclerotic vascular diseases
and type 2 diabetes development, is a state of hyperse-
cretion of pro-atherogenic, pro-inflammatory, and pro-
diabetic adipocytokines [38]. Similarly, such characteris-
tics were found in the T3 group of this study: athero-
genic lipid profiles (high TG, TC, LDL-cholesterol,
and apolipoprotein B and low HDL-cholesterol), in-
flammation (high hs-CRP), and risk of IR (high insu-
lin and HOMA-IR). These features are similar to
those that can be observed in individuals with excess
visceral fat area [18, 19]. Therefore, adipose tissue
dysfunction might have existed in the T3 group be-
cause of large visceral fat accumulation.
In summary, we found that excess visceral fat (greater
than 99.6 cm2 in case of this study) may be associated
with changes in circulating fatty acid composition, al-
tered activities of fatty acid desaturases that disturb
plasma fatty acid metabolism, and adipose tissue dys-
function. As discussed so far, such changes are related to
cardiovascular diseases and/or type 2 diabetes; thus, vis-
ceral fat area should be observed to prevent these
diseases.
The present study has several limitations. First, we
only analyzed overweight Korean subjects. Body struc-
ture and habitual diets can differ substantially between
races and countries. Second, this study is observational;
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thus, the causal relationship between fatty acid pattern
and visceral fat area in overweight subjects was not
proven. Third, we did not analyze fatty acids from each
lipid fraction but rather from total lipids. Despite these
limitations, the main finding of this study is that the dif-
ferent fatty acid composition in each overweight individ-
ual is due to different desaturase activities with
increasing visceral fat area. Therefore, the results of the
present study support the assumption that increased ac-
tivities of C16 Δ9-desaturase and C18 Δ9-desaturase in
parallel with decreased Δ5-desaturase activity may be a
causative factor in disturbed fatty acid metabolism in
overweight subjects with a high visceral fat area, particu-
larly with the SFAs, MUFAs, and n-6 PUFA series.
Further high-quality studies including polymorphism
analysis of fatty acid desaturases are required for a better
understanding of the potential role of SFAs, MUFAs,
and n-6 and n-3 PUFAs in the development and conse-
quences of overweight/obesity with high visceral fat.
Conclusion
Our results suggest that increased visceral fat area causes
alterations in individual fatty acid levels and that altered
desaturase activity due to visceral fat accumulation af-
fects the composition of circulating fatty acids for the
worse. These data support the assumption that increased
activities of C16 Δ9-desaturase and C18 Δ9-desaturase in
parallel with decreased Δ5-desaturase activity may result
in disturbed fatty acid metabolism in overweight subjects
with a high visceral fat area, particularly with the SFAs,
MUFAs, and n-6 PUFA series. Additionally, atherogenic
traits are worsened and adipose tissue dysfunction may
occur in overweight subjects with large visceral fat accu-
mulation. Therefore, individuals with high visceral fat area
should focus on treating and preventing cardiovascular
diseases.
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